trending Market Intelligence /marketintelligence/en/news-insights/trending/eevihpmrgkd4kdc4vfo69q2 content esgSubNav
In This List

Celgene cancer cocktail improves survival of blood cancer patients

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Celgene cancer cocktail improves survival of blood cancer patients

Celgene Corp. said adding two of its cancer medicines with bortezomib improved the survival of blood cancer patients who did not respond to prior therapy.

The company was studying a combination of Pomalyst, Imnovid and bortezomib with low-dose dexamethasone, an anti-inflammatory and immunosuppressant drug, in a late-stage study known as Optimismm.

The phase 3 trial achieved its primary endpoint of showing a statistically significant and clinically meaningful improvement in progression-free survival in patients with relapsed or refractory multiple myeloma.

The cancer cocktail was being evaluated against a combination of bortezomib, marketed as Velcade by Takeda Pharmaceutical Co. Ltd., and low-dose dexamethasone.

Patients in the study had previously been treated with Revlimid, or lenalidomide, a Celgene medicine approved for multiple myeloma.